Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia
This trial is active, not recruiting.
|Treatments||chlorambucil, cyclophosphamide, fludarabine phosphate|
|Sponsor||European Organisation for Research and Treatment of Cancer - EORTC|
|Start date||March 2001|
|Trial identifier||NCT00017108, CDR0000068650, EORTC-06992-CLL-3|
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which chlorambucil regimen is more effective in treating advanced chronic lymphocytic leukemia.
PURPOSE: Randomized phase III trial to determine the effectiveness of different regimens of chlorambucil in treating patients who have advanced chronic lymphocytic leukemia.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Brussels, Belgium||Cliniques Universitaires Saint-Luc||no longer recruiting|
|Brussels, Belgium||Hopital Universitaire Erasme||no longer recruiting|
|Haine Saint Paul, Belgium||Hopital de Jolimont||no longer recruiting|
|Olomouc, Czech Republic||University Hospital - Olomouc||no longer recruiting|
|Kaposvar, Hungary||County Hospital||no longer recruiting|
|Messina, Italy||Azienda Ospedaliera Papardo||no longer recruiting|
|Rome, Italy||Ospedale Sant' Eugenio||no longer recruiting|
|Skopje, Macedonia, The Former Yugoslav Republic of||Clinical Center Skopje||no longer recruiting|
|'s-Gravenhage, Netherlands||Leyenburg Ziekenhuis||no longer recruiting|
|Amsterdam, Netherlands||Onze Lieve Vrouwe Gasthuis||no longer recruiting|
|Leiden, Netherlands||Leiden University Medical Center||no longer recruiting|
|Nijmegen, Netherlands||University Medical Center Nijmegen||no longer recruiting|
|Porto, Portugal||Hospital Escolar San Joao||no longer recruiting|
Male or female participants from 18 years up to 75 years old.
DISEASE CHARACTERISTICS: - Diagnosis of B-cell chronic lymphocytic leukemia - Co-expression of CD5/CD19 or CD5/CD20 positivity, dim sIg, and CD23 positivity - Previously untreated advanced disease defined as presence of at least 1 of the following: - Total tumor mass (TTM) score greater than 9 - TTM doubling time less than 12 months - Bone marrow failure (platelet count less than 100,000/mm^3 and/or hemoglobin less than 10 g/dL) PATIENT CHARACTERISTICS: Age: - 18 to 75 Performance status: - WHO 0-2 Life expectancy: - Not specified Hematopoietic: - See Disease Characteristics Hepatic: - Bilirubin less than 3 times upper limit of normal (ULN) - Hepatitis B negative - No active hepatitis C Renal: - Creatinine less than 3 times ULN OR - Creatinine clearance greater than 0.5 times normal Cardiovascular: - No severe cardiovascular disease - No arrhythmia requiring chronic treatment - No New York Heart Association class III or IV congestive heart failure - No symptomatic ischemic heart disease Other: - No uncontrolled systemic infection - HIV negative - No prior or concurrent uncontrolled malignancy - No prior or concurrent central nervous system or psychiatric disorders requiring hospitalization - No psychological, familial, sociological, or geographical condition that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior biologic therapy Chemotherapy: - No prior chemotherapy Endocrine therapy: - Prior steroid therapy for less than 2 weeks allowed Radiotherapy: - No prior radiotherapy Surgery: - Not specified
|Official title||Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3)|
|Description||OBJECTIVES: - Compare overall and disease-related survival of patients with B-cell chronic lymphocytic leukemia treated with high-dose chlorambucil induction therapy with or without low-dose chlorambucil maintenance therapy. - Compare the time to salvage treatment in these patients treated with these regimens. - Compare the toxic effects of these regimens in these patients. - Compare the treatment-related mortality of these patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, time to complete response (before 12 weeks vs after 12 weeks vs partial response), and cytopenia at diagnosis (Binet stage A+B vs C). All patients receive induction therapy comprising high-dose oral chlorambucil daily. Treatment continues until achievement of complete response or a maximum of 24 weeks in the absence of disease progression or unacceptable toxicity. Patients who respond to induction therapy are randomized to 1 of 2 treatment arms for maintenance therapy. - Arm I: Patients receive low-dose oral chlorambucil twice a week. Therapy continues for up to 5 years in the absence of disease progression or unacceptable toxicity. If disease progression occurs, then patients may proceed to salvage therapy. - Arm II: Patients receive no maintenance therapy. If disease progresses, patients receive induction therapy again. If disease does not respond to re-induction therapy, then patients may proceed to salvage therapy. - Salvage therapy: Patients with progressive disease during maintenance therapy receive fludarabine IV daily and cyclophosphamide IV daily on days 1-3. Treatment repeats every 4 weeks for 3-6 courses. Patients are followed monthly for 3 months, every 2 months for 6 months, and then every 3 months thereafter. PROJECTED ACCRUAL: Approximately 470 patients will be accrued for this study within 4.7 years.|
Call for more information